Low Blood Sugar Poses Unaddressed Threat to People with Type 2 Diabetes

Endocrine Society analysis identifies hypoglycemia as an ongoing gap in diabetes care

New research from the Endocrine Society and Avalere Health finds that clinicians lack the resources to identify, assess and manage patients who are at a high risk of developing hypoglycemia, or episodes of dangerously low blood sugar.

The analysis was published in The Journal of Clinical Endocrinology & Metabolism. The study examined available resources for managing hypoglycemia and opportunities to incorporate better management strategies in clinical practice. Hypoglycemia is particularly common in adults who have type 2 diabetes and are 65 and older.

To develop the analysis, experts from the Society and Avalere Health conducted an environmental scan that examined clinical guidance documents, quality measures and their use in value-based purchasing programs, clinical tools and quality initiatives related to type 2 diabetes and hypoglycemia. The authors found more than 750 relevant scientific articles published in the last five years and examined 31 in detail.

The analysis suggests that efforts to prevent hypoglycemia should focus on helping primary care providers identify high-risk patients who would most benefit from individualized glycemic targets and educating at-risk patients about how to recognize and appropriately manage hypoglycemic events.

While some tools exist to help healthcare providers identify individuals at high risk of hypoglycemia, they are not in widespread use.

Severe hypoglycemia can cause seizures, loss of consciousness and death. One recent meta-analysis concluded that individuals who take insulin to treat type 2 diabetes experience an average of 23 mild or moderate events and one severe hypoglycemic episode in a year.

“While hypoglycemia is well recognized as a threat among people with type 1 diabetes and their healthcare providers, the danger it poses to people with type 2 diabetes is underappreciated,” says the Society’s chief professional & clinical affairs officer Robert W. Lash, MD, the first author of the analysis. “In the past two decades, healthcare providers and patients have made important strides to achieve improved blood glucose control to prevent or delay complications such as heart, eye and kidney disease. However, we need to be aware that emphasizing these lower blood glucose goals may unintentionally put individuals with type 2 diabetes at greater risk of hypoglycemia.”

A study of Medicare beneficiaries conducted between 1999 and 2011, for instance, found that quality metrics encouraging increased adherence to a targeted blood glucose goal had successfully reduced hospital admission rates for hyperglycemia, or elevated blood glucose levels, but hospitalizations resulting from hypoglycemia rose during the same timeframe.

The environmental scan paves the way for the Society’s Hypoglycemia Prevention Initiative to  to improve outcomes in individuals with type 2 diabetes. The Initiative will include a pilot study to test ways to address the clinical care gaps identified in the analysis.

The Initiative’s goals include identifying patients who are at high risk in a timely manner, supporting appropriate clinical interventions that can be administered in primary care providers’ offices and clinics, and decreasing the frequency and severity of hypoglycemia episodes. The effort brings together various healthcare stakeholders including endocrinologists, primary care providers, health plans, diabetes educators, and individuals with type 2 diabetes.

“The current landscape clearly demonstrates the need to address hypoglycemia as a routine part of clinical care for individuals with type 2 diabetes,” Lash says. “Now that we understand the full scope of the issue, the Society’s Hypoglycemia Prevention Initiative is poised to develop needed support tools for clinicians and to raise awareness of the problem among both healthcare providers and people with diabetes.”

You may also like

  • Liraglutide Increases Insulin Sensitivity Independent of Weight Loss, Study Shows

    Liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat type 2 diabetes and obesity, can lead to rapid improvement in insulin sensitivity, according to a study recently published in Diabetes. “We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on…

  • COVID-19 Vaccines and Hyperglycemia in Patients with Type 1 Diabetes

    While proven to be safe, the COVID-19 vaccines could cause some people with type 1 diabetes to see their blood sugar to temporarily spike. The key for both patient and provider is to remain vigilant with glucose testing and insulin dosing post-jab to maintain glycemic control.  In the summer of 2021, a 24-year-old woman presented…